NCT04815356View on ClinicalTrials.gov

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

December 1, 2036

Study Completion Date

December 1, 2036

Conditions
Hairy Cell LeukemiaHairy Cell Leukemia Variant
Interventions
BIOLOGICAL

CD22CART cell infusion

The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 participants will be evaluated for response at Day 28 post-CD22CART infusion.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH